Yazar "Saylan, M." için listeleme

Toplam kayıt 7, listelenen: 1-7

Cost Analysis of Complications With Coronary Artery Disease Or Peripheral Artery Disease in Turkey

Kockaya, G.; Ergin, Oguzhan G.; Caliskan, Z.; Kurnaz, M.; Okcun, S.; Buyuktuna, N.; Saylan, M. (Elsevier Science Inc, 2019)

…
Cost Effectiveness of Rivaroxaban For Stroke Prevention in Atrial Fibrillation Patients For Ttr and Chads2 Score in Turkey

Ergin, Oguzhan G.; Kockaya, G.; Caliskan, Z.; Okcun, S.; Kurnaz, M.; Buyuktuna, N.; Saylan, M. (Elsevier Science Inc, 2019)

…
Cost Effectiveness of Rivaroxaban in Coronary Artery Disease And/Or Peripheral Artery Disease For 5 Differen Patient Sub-Groups in Turkey

Kockaya, G.; Ergin, Oguzhan G.; Caliskan, Z.; Okcun, S.; Kurnaz, M.; Buyuktuna, N.; Saylan, M. (Elsevier Science Inc, 2019)

…
Effect of Time in Therapeutic Range on Cost and Clinical Outcomes of Atrial Fibrilation Patients : A Cost-Consequences Analysis of Rivaroxaban Vs Warfarin For Turkey

Kockaya, G.; Cavus, F.; Ozin, B.; Yilmaz, K. C.; Ciftci, O.; Ergin, Oguzhan G.; Saylan, M. (Elsevier Science Inc, 2018)

…
Expert Analysis on Cost Analysis of Management of Cardiovascular Disease Co-Morbidities

Kockaya, G.; Cavus, F.; Ozin, B.; Yilmaz, K. C.; Ciftci, O.; Ergin, Oguzhan G.; Saylan, M. (Elsevier Science Inc, 2018)

…
Patient Access To Orphan Medicines in Turkey

Kockaya, G.; Ergin, Oguzhan G.; Kurnaz, M.; Okcun, S.; Talay, D.; Gedik, Sar C.; Saylan, M. (Elsevier Science Inc, 2019)

…
Patient Access To Personalized Oncology Medicines in Turkey

Ergin, Oguzhan G.; Kockaya, G.; Okcun, S.; Kurnaz, M.; Gedik, Sar C.; Saylan, M. (Elsevier Science Inc, 2019)

…